Medexus Pharmaceuticals Inc.

TSX:MDP Stock Report

Market Cap: CA$41.1m

Medexus Pharmaceuticals Management

Management criteria checks 3/4

Medexus Pharmaceuticals' CEO is Ken d'Entremont, appointed in Dec 2018, has a tenure of 5.5 years. total yearly compensation is $882.21K, comprised of 45.3% salary and 54.7% bonuses, including company stock and options. directly owns 5.98% of the company’s shares, worth CA$2.46M. The average tenure of the management team and the board of directors is 4.2 years and 5.7 years respectively.

Key information

Ken d'Entremont

Chief executive officer

US$882.2k

Total compensation

CEO salary percentage45.3%
CEO tenure5.5yrs
CEO ownership6.0%
Management average tenure4.2yrs
Board average tenure5.7yrs

Recent management updates

Recent updates

The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet

Jun 15
The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet

Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden

Apr 25
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden

Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive

Mar 03
Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive

Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story

Jan 06
Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story

Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors

Oct 11
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors

Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Sep 11
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky

Jan 19
Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky

Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Sep 22
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Is Medexus Pharmaceuticals (TSE:MDP) Weighed On By Its Debt Load?

Dec 16
Is Medexus Pharmaceuticals (TSE:MDP) Weighed On By Its Debt Load?

Medexus Pharmaceuticals Inc. (TSE:MDP) Analysts Just Cut Their EPS Forecasts Substantially

Aug 21
Medexus Pharmaceuticals Inc. (TSE:MDP) Analysts Just Cut Their EPS Forecasts Substantially

Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Aug 04
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Medexus Pharmaceuticals Inc. (CVE:MDP): When Will It Breakeven?

May 04
Medexus Pharmaceuticals Inc. (CVE:MDP): When Will It Breakeven?

The Independent Director of Medexus Pharmaceuticals Inc. (CVE:MDP), Michael Mueller, Just Bought 34% More Shares

Feb 26
The Independent Director of Medexus Pharmaceuticals Inc. (CVE:MDP), Michael Mueller, Just Bought 34% More Shares

CEO Compensation Analysis

How has Ken d'Entremont's remuneration changed compared to Medexus Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

US$6m

Sep 30 2023n/an/a

US$5m

Jun 30 2023n/an/a

US$3m

Mar 31 2023US$882kUS$400k

US$1m

Dec 31 2022n/an/a

-US$11m

Sep 30 2022n/an/a

-US$11m

Jun 30 2022n/an/a

US$2m

Mar 31 2022US$592kUS$400k

-US$3m

Dec 31 2021n/an/a

-US$8m

Sep 30 2021n/an/a

-US$20m

Jun 30 2021n/an/a

-US$31m

Mar 31 2021US$688kUS$328k

-US$28m

Dec 31 2020n/an/a

-US$19m

Sep 30 2020n/an/a

-US$9m

Jun 30 2020n/an/a

-US$7m

Mar 31 2020US$385kUS$300k

-US$5m

Dec 31 2019n/an/a

-US$4m

Sep 30 2019n/an/a

-US$3m

Jun 30 2019n/an/a

-US$6m

Mar 31 2019US$2mUS$144k

-US$5m

Compensation vs Market: Ken's total compensation ($USD882.21K) is above average for companies of similar size in the Canadian market ($USD175.69K).

Compensation vs Earnings: Ken's compensation has been consistent with company performance over the past year.


CEO

Ken d'Entremont

5.5yrs

Tenure

US$882,209

Compensation

Mr. Kenneth d'Entremont, also known as Ken, has been Chief Executive Officer at Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) since December 2018 and served as its Chief Operating Officer since O...


Leadership Team

NamePositionTenureCompensationOwnership
Kenneth d'Entremont
CEO & Director5.5yrsUS$882.21k5.98%
$ 2.5m
Marcel Konrad
Chief Financial Officer2.9yrsUS$702.56k0.33%
$ 134.4k
Ian Wildgoose Brown
General Counsel & Corporate Secretary2.6yrsUS$464.02k0.084%
$ 34.7k
Tina Byers
Executive of Investor Relationsno datano datano data
Bill Poncy
Senior Vice President of Commercial Operations - United States5.7yrsUS$439.69kno data
Brian Peters
Vice President of Sales & Marketing - United Statesno dataUS$281.91kno data

4.2yrs

Average Tenure

Experienced Management: MDP's management team is considered experienced (4.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kenneth d'Entremont
CEO & Director5.7yrsUS$882.21k5.98%
$ 2.5m
Michael Mueller
Independent Chairman10.1yrsUS$139.92k0.37%
$ 151.0k
Benoit Gravel
Independent Director6.8yrsUS$145.95k0.23%
$ 94.7k
Stephen Nelson
Independent Director5.7yrsUS$124.92k2.24%
$ 919.1k
Nancy Phelan
Independent Directorless than a yearno datano data
Harmony Garges
Independent Director1.3yrsUS$60.18k0.054%
$ 22.3k
Menassie Taddese
Independent Director1.3yrsUS$60.18k0.054%
$ 22.3k

5.7yrs

Average Tenure

55yo

Average Age

Experienced Board: MDP's board of directors are considered experienced (5.7 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.